---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-24-000138"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2024-10-15T23:59:59+00:00"
generated_at: "2026-05-30T15:08:33.361690+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Exelixis enters clinical collaboration with Merck for zanzalintinib combo trials in HNSCC and RCC

## Summary
- Collaboration covers zanzalintinib + KEYTRUDA in phase 3 HNSCC trial (STELLAR-305) and zanzalintinib + WELIREG in RCC phase 1/2 and two phase 3 trials.
- Merck supplies KEYTRUDA and sponsors one RCC phase 3; Exelixis co-funds phase 1/2 and other phase 3, supplies zanzalintinib and cabozantinib.
- Exelixis retains all global commercial and marketing rights to zanzalintinib.

## SEC filing metadata
- accession: 0000939767-24-000138
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2024-10-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976724000138/0000939767-24-000138-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976724000138/exel-20241014.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-24-000138
- JSON: https://secwatch.observer/filing/0000939767-24-000138.json
- Plain text: https://secwatch.observer/filing/0000939767-24-000138.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.